NCT07070219View on ClinicalTrials.gov

A Study of CTD402 in T-ALL/LBL Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

December 30, 2028

Conditions
Acute Lymphocytic Leukemia RefractoryLymphoma, Lymphoblastic
Interventions
DRUG

CTD402 CAR T Cell Injection

CAR T cells

Trial Locations (4)

11101

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

37203

NOT_YET_RECRUITING

Sarah Cannon Research Insitute, Nashville

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

94304

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
lead

BIOHENG THERAPEUTICS US LLC

INDUSTRY

NCT07070219 - A Study of CTD402 in T-ALL/LBL Patients | Biotech Hunter | Biotech Hunter